Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADELANTE SQY44
- Development stage
- Preclinical
- Lead developer
- Sqy Therapeutics
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
ADELANTE SQY44 is a tricyclo-DNA (tcDNA) antisense oligonucleotide designed to treat Duchenne muscular dystrophy (DMD). Developed by Sqy Therapeutics, the candidate is engineered to induce exon 44 skipping in the DMD pre-mRNA. By skipping exon 44, the therapy aims to restore the translational reading frame of the dystrophin gene, allowing for the production of an internally truncated but functional dystrophin protein to slow or prevent muscle degeneration.
02
Targets
DMD (Dystrophin)
Beyond the preview
Go deeper on ADELANTE SQY44.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADELANTE SQY44.